BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS

NEXT STORY
Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors
PREV STORY
Prospective Study Finds Potential Utility of MeMed’s Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Trillium Therapeutics to Report Preclinical Data on Its STING Program at the SITC 34th Annual Meeting

author_avatar
NASDAQ Market News

Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2017 Results

MORRIS PLAINS, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or ...

author_avatar
NASDAQ Market News

NICE Issues Draft Guidance on the Use of gammaCore for Cluster Headache

author_avatar
NASDAQ Market News